You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 7, July 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group

R. W. Beart Jr, C. G. Moertel, H. S. Wieand, J. E. Leigh, H. E. Windschitl, J. A. van Heerden, R. J. Fitzgibbons Jr and B. G. Wolff
Mayo Clinic, Scottsdale, Ariz.

We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion. Randomization was accomplished during surgery after staging by frozen section. Only 5 (2.2%) of our 224 patients were ineligible, but an additional 10 patients assigned to portal vein infusion could not be treated because of technical problems with catheter placement. Toxic reactions were mild. There was only 1 postoperative death on each study arm. At present, the median follow-up for all patients is 5.5 years (range, 1.5 to 9.5 years). Interval to progression and survival curves essentially overlap. The same lack of treatment effect is seen in both the stage B and C subsets.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adjuvant Treatment of Colorectal Cancer
Wolpin et al.
CA Cancer J Clin 2007;57:168-185.
ABSTRACT | FULL TEXT  

Prognostic Effect of Perioperative Change of Serum Carcinoembryonic Antigen Level: A Useful Tool for Detection of Systemic Recurrence in Rectal Cancer
Park et al.
Ann. Surg. Oncol. 2006;13:645-650.
ABSTRACT | FULL TEXT  

Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group
Figueredo et al.
JCO 2004;22:3395-3407.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Benson et al.
JCO 2004;22:3408-3419.
ABSTRACT | FULL TEXT  

Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Ribic et al.
NEJM 2003;349:247-257.
ABSTRACT | FULL TEXT  

Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer
Allegra et al.
JCO 2002;20:1735-1743.
ABSTRACT | FULL TEXT  

Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers
Halling et al.
JNCI J Natl Cancer Inst 1999;91:1295-1303.
ABSTRACT | FULL TEXT  

Raltitrexed and the treatment of advanced colorectal cancer
Summerhayes
J Oncol Pharm Pract 1996;2:225-235.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.